IP Verse

Mrna Therapy For The Treatment Of Ocular Diseases - EP3122878

The patent EP3122878 was granted to Shire Human Genetic Therapies on Oct 24, 2018. The application was originally filed on Mar 19, 2015 under application number EP15767977A. The patent is currently recorded with a legal status of "Opposition Rejected".

EP3122878

SHIRE HUMAN GENETIC THERAPIES
Application Number
EP15767977A
Filing Date
Mar 19, 2015
Status
Opposition Rejected
Mar 5, 2021
Grant Date
Oct 24, 2018
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

PRUFER & PARTNER MBBJul 24, 2019PRUFER & PARTNER MBB PATENTANWALTE RECHTSANWALTE -

Patent Citations (24) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
EXAMINATIONWO2013151671
INTERNATIONAL-SEARCH-REPORTUS2006241071
INTERNATIONAL-SEARCH-REPORTUS2013266640
INTERNATIONAL-SEARCH-REPORTWO2012170930
OPPOSITIONUS2009011040
OPPOSITIONUS2012321719
OPPOSITIONWO2012170930
OPPOSITIONWO2013090648
OPPOSITIONWO2013093029
OPPOSITIONWO2013151671
OPPOSITIONWO2013151672
OTHEREP2656837
OTHERUS2009011040
OTHERUS2012002012
OTHERUS2012321719
OTHERUS2013266640
OTHERWO2006123248
OTHERWO2008083949
OTHERWO2012170930
OTHERWO2013093029
OTHERWO2013151671
SEARCHUS2013266640
SEARCHWO2006110813
SEARCHWO2013149140

Non-Patent Literature (NPL) Citations (15) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
OPPOSITION- KUHN et al., "mRNA as a Versatile Tool for Exogenous Protein Expression", Current Gene Therapy, (20121000), vol. 12, no. 5, pages 347 - 361, XP008159357-
OPPOSITION- SOMMER et al., "The size distributions of proteins, mRNA, and nuclear", J. Mol. Evol., (19800300), vol. 15, no. 3, pages 37 - 57, XP055626111-
OPPOSITION- APAOLAZA et al., "A novel gene therapy vector based on hyaluronic acid and solid lipid nanoparticles for ocular diseases", Int J Pharm , 2013, (20140224), vol. 465, no. 1-2, pages 413 - 426, XP028837215
OPPOSITION- BOCHOT et al., "Liposomes for intravitreal drug delivery: A state of the art", Journal of Controlled Release, (20120125), vol. 161, no. 2, pages 628 - 634, XP028492689
OPPOSITION- CAI et al., "Nanoparticle applications in ocular gene therapy", Vision Res., (20080200), vol. 48, no. 3, pages 319 - 24, XP022452224
OPPOSITION- KORMANN et al., "Expression of therapeutic proteins after delivery of chemically modified mRNA in mice", Nat Biotech, (201102), vol. 29, no. 2, pages 154 - 157, XP055040839
OPPOSITION- NAG et al., "Surface Engineering of Liposomes for Stealth Behavior", Pharmaceutics, (20131025), vol. 5, no. 4, pages 541 - 569, XP055156434
OPPOSITION- HE et al., "New options for uveitis treatment", Int J Ophthalmol. 2013, (20131018), vol. 6, no. 5, pages 702 - 707, XP055411843
OPPOSITION- KHAR et al., "Nano-vectors for the Ocular Delivery of Nucleic Acid-based Therapeutics", Indian J Pharm Sci., (20101100), vol. 72, no. 6, pages 675 - 688, XP055182875
OPPOSITION- KUHN et al., "Determinants of intracellular RNA pharmacokinetics", RNA Biology, (20110100), vol. 8, no. 1, pages 35 - 43, XP055175365
OTHER- APAOLAZA et al., "A novel gene therapy vector based on hyaluronic acid and solid lipid nanoparticles for ocular diseases", Int J Pharm, (20130000), vol. 465, no. 1-2, pages 413 - 426, XP028837215
OTHER- CAI et al., "Nanoparticle applications in ocular gene therapy", Vision Res., (20080200), vol. 48, no. 3, pages 319 - 324, XP022452224
OTHER- KORMANN et al., "Expression of therapeutic proteins after delivery of chemically modified mRNA in mice", Nat Biotech, (20110200), vol. 29, no. 2, pages 154 - 157, XP055040839
OTHER- DEL POZO-RODRIGUEZ, "Lipid Nanoparticles as drug/Gene Delivery Systems to the Retina", J Ocul Pharmacol Ther., (20130300), vol. 29, no. 2, pages 173 - 188, XP055411997
OTHER- HE et al., "New options for uveitis treatment", Int J Ophthalmol., (20131018), vol. 6, no. 5, pages 702 - 707, XP055411843

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents